about
Entering new areas in known fields: recombinant fusion protein linking recombinant factor VIIa with recombinant albumin (rVIIa-FP) - advancing the journeyInherited bleeding disorder due to familial type 2 platelet cyclo-oxygenase deficiencyAlpha cyano-4-hydroxy-3-methoxycinnamic acid inhibits proliferation and induces apoptosis in human breast cancer cellsGlobal Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate).Safety and efficacy of three arthroscopic procedures using Holmium: Yag laser in two high-responder haemophiliacs.In vitro tests for assessing heparin-induced thrombocytopenia in patients after elective hip replacement. A medico-economical evaluation.Identification of new and known polymorphisms in glycoprotein IIb and IIIa genes by denaturing gradient gel electrophoresis.A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study.[Assessment of the interest of using confirmatory test in ELISA with use of high concentration of heparin-induced thrombocytopenia].Prospective evaluation of automatized PF4/heparin immunoassays HemosIL HIT-ab (PF4-H) for the diagnosis of heparin-induced thrombocytopenia.A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal.The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa.Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.Coagulation factor concentrates: past, present, and future.Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trialStandardisation of thrombin generation test--which reference plasma for TGT? An international multicentre study.MDA-9/syntenin is essential for factor VIIa-induced signaling, migration, and metastasis in melanoma cellsCharacterization of an autosomal dominant bleeding disorder caused by a thrombomodulin mutation.Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.New approaches to using FEIBA in the treatment of inhibitor patients.Basic aspects of bypassing agents.Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives.Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Optimizing on-demand treatment with NovoSeven room temperature stable.New developments in laboratory diagnosis and monitoring.Consensus recommendations for the use of FEIBA(®) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity.Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer.The first recombinant FVIII produced in human cells--an update on its clinical development programme.Spectrum of the mutations in Bernard-Soulier syndrome.Spotlight on the human factor: building a foundation for the future of haemophilia A management: report from a symposium on human recombinant FVIII at the World Federation of Hemophilia World Congress, Melbourne, Australia on 12 May 2014.Safety update on the use of recombinant activated factor VII in approved indications.Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement.First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.Usefulness of an in vitro cellular expression model for haemophilia A carrier diagnosis: illustration with five novel mutations in the F8 gene in women with isolated factor VIII:C deficiency.Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.Characterization of four novel molecular changes in the promoter region of the factor VIII gene.Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
P50
Q26747079-6B505CA4-3CD4-4740-A7F1-8AC32A7EBCAFQ28192133-50F1D07B-56FE-43E6-8B0C-2089D4D35898Q28536827-8B0474F1-4DB3-4AF2-8FA4-4C6E0D655782Q31041664-37761E87-7E88-4207-91C6-7F37176EE9E7Q31396429-C05EA416-6E63-4804-9669-5F4211A8CEA0Q33344827-52EFA83A-2764-4669-9D96-E1E6342B093BQ33371674-7870B8BF-8B9A-44AE-BD1F-FFDA9C75A542Q33384200-813F190F-2B8D-465C-9BBF-6E9A7121F341Q33392031-C08E5425-37C8-4C63-9DF9-BCB6AE789FF5Q33416580-E551886F-003A-4DBA-83D9-A28A5FC80F8AQ33754796-61C9A8D0-1D73-45B6-B9EE-0C7819052730Q34090287-CA934AA1-82BE-4B89-A7E1-EE99C3E0D4A1Q34458077-3848456D-C8BA-4126-9EDF-F3C967A9B22FQ34659834-E1B5ACD1-DBDE-4A14-91F9-BA32ACD66191Q34737483-8C8F895B-F17F-4438-92E6-98230424BFF5Q35014747-91DE85A5-8BDF-49A8-AE63-6FFC70AE3D81Q35055504-8D1D08BE-7203-4F05-BE0A-B0E14DA1D1C2Q35126279-58CB169F-DA8A-4E70-B605-6711D36FD040Q36250920-5E12D8D0-7EF4-4B18-B1E5-A744E7FDCAB0Q36521385-A7217DF6-7D9C-40E7-B98C-70F909C91171Q36661832-C26ADF9E-0518-4104-B166-55EE7D9E3317Q36818527-F1C512CD-44E1-4AB4-8B91-BE639FFF700BQ37185097-3A2E2D71-6AA0-47E3-AD88-5EE30920CB9DQ37768482-CCC10609-3D6D-4D0D-9AFF-A7EAF78A79E3Q37768873-2D76DDD7-8028-48D8-8FDC-5DEAB3EAD3FAQ38044492-3A1F3D2E-BA63-4FB9-B2FC-A310398B7A85Q38093667-B4BCBA36-F38B-45E4-BEDE-5D50B89361A5Q38130058-F2DD27F1-9252-4A0C-BAF8-7A9AA90BE100Q38170563-54F713EC-5521-4C7C-8FE8-2EAE979CB2F3Q38220681-104D738C-DBE0-4DEE-8DDA-8824A6EFCFDCQ38282775-252B752C-2036-45E0-957B-F504C4790710Q38527506-DEED4D45-4448-4DF6-ABD3-2711F763845AQ38739383-D0790DE7-9B49-48CC-B3CA-F88F0D4CB3E9Q38805417-82308852-A041-4D5F-8ECC-A1B06DDED8FFQ38873929-1EB89B26-38B0-4178-9884-C232F4E0F233Q38896886-362CD3ED-89D2-4A12-97D8-5F52CC32B69AQ38906777-E143D106-9983-44BE-ABF3-07E16E706603Q38944641-4DDEE3A6-68F4-42A4-8060-FFCBC5AC681AQ39039126-C8DCB0E5-775A-4C1E-9680-BF543F8D1B6FQ39952685-EC81A13D-5C7E-4910-9D63-72DD3C87554A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
C Negrier
@ast
C Negrier
@en
C Negrier
@es
C Negrier
@nl
type
label
C Negrier
@ast
C Negrier
@en
C Negrier
@es
C Negrier
@nl
prefLabel
C Negrier
@ast
C Negrier
@en
C Negrier
@es
C Negrier
@nl
P106
P31
P496
0000-0003-3569-0366